MYC is the most broadly deregulated oncogene in a wide range of malignant tumors, whereas MYCN is frequently amplified in neural tumors such as neuroblastoma and small cell lung carcinoma, and MYCL amplifications are solely reported in small cell lung carcinoma1,3. Here, MYCN is linked to cancer.